|
[1]
|
Ottaviani, G. and Jaffe, N. (2009) The Epidemiology of Osteosarcoma. Cancer Treatment and Research, 152, 3-13. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Bielack, S.S., Kempf-Bielack, B., Delling, G., et al. (2002) Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1, 702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. Journal of Clinical Oncology, 20, 776-790. [Google Scholar] [CrossRef]
|
|
[3]
|
Bielack, S., Jürgens, H., Jundt, G., et al. (2009) Osteosarcoma: The COSS Experience. Cancer Treatment and Research, 152, 289-308. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Ozaki, T., Flege, S., Liljenqvist, U., et al. (2002) Osteosarcoma of the Spine: Experience of the Cooperative Osteosarcoma Study Group. Cancer, 94, 1069-1077. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Luetke, A., Meyers, P.A., Lewis, I., et al. (2014) Osteosarcoma Treatment—Where Do We Stand? A State of the Art Review. Cancer Treatment Reviews, 40, 523-532. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Wittig, JC., Bickels, J., Priebat, D., et al. (2002) Osteosarcoma: A Multidisciplinary Approach to Diagnosis and Treatment. American Family Physician, 65, 1123-1132.
|
|
[7]
|
Kager, L., Tamamyan, G. and Bielack, S. (2017) Novel Insights and Therapeutic Interventions for Pediatric Osteosarcoma. Future Oncology, 13, 357-368. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Normand, R. and Yanai, I. (2013) An Introduction to High-Throughput Sequencing Experiments: Design and Bioinformatics Analysis. Methods in Molecular Biology, 1038, 1-26. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Canzoneri, R., Lacunza, E. and Abba, M.C. (2019) Genomics and Bioinformatics as Pillars of Precision Medicine in Oncology. Medicina, 79, 587-592.
|
|
[10]
|
Shulaev, V. (2006) Metabolomics Technology and Bioinformatics. Briefings in Bioinformatics, 7, 128-139. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Angarica, V.E. and Del Sol, A. (2017) Bioinformatics Tools for Genome-Wide Epigenetic Research. Advances in Experimental Medicine and Biology, 978, 489-512. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Wang, Y., Zhao, Y., Bollas, A., et al. (2021) Nanopore Sequencing Technology, Bioinformatics and Applications. Nature Biotechnology, 39, 1348-1365. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Zeng, Y. and Fan, R. (2022) Identification and Verification of CCNB1 as a Potential Prognostic Biomarker by Comprehensive Analysis. Scientific Reports, 12, Article No. 16153. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Chen, E.B., Qin, X., Peng, K., et al. (2019) HnRNPR-CCNB1/CENPF Axis Contributes to Gastric Cancer Proliferation and Metastasis. Aging, 11, 7473-7491. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Simpson, E. and Brown, H.L. (2018) Understanding Osteosarcomas. Journal of the American Academy of Physician Assistants, 31, 15-19. [Google Scholar] [CrossRef]
|
|
[16]
|
Yang, C., Tian, Y., Zhao, F., et al. (2020) Bone Microenvironment and Osteosarcoma Metastasis. International Journal of Molecular Sciences, 21, Article 6985. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Nomura, M., Rainusso, N., Lee, YC., et al. (2019) Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. JNCI: Journal of the National Cancer Institute, 111, 1216-1227. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Krishnan, K., Khanna, C. and Helman, L.J. (2005) The Biology of Metastases in Pediatric Sarcomas. The Cancer Journal, 11, 306-313. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Malumbres, M. and Barbacid, M. (2009) Cell Cycle, CDKs and Cancer: A Changing Paradigm. Nature Reviews Cancer, 9, 153-166. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Vishnoi, N. and Yao, J. (2017) Single-Cell, Single-MRNA Analysis of Ccnb1 Promoter Regulation. Scientific Reports, 7, Article No. 2065. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Liu, D., Xu, W., Ding, X., et al. (2017) Polymorphisms of CCNB1 Associated with the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients. Journal of Cancer, 8, 3785-3794. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Brcic, L., Heidinger, M., Sever, AZ., et al. (2019) Prognostic Value of Cyclin A2 and B1 Expression in Lung Carcinoids. Pathology, 51, 481-486. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Zhan, Q., Antinore, M.J., Wang, X.W., et al. (1999) Association With Cdc2 and Inhibition of Cdc2/Cyclin B1 Kinase Activity by the P53-Regulated Protein Gadd45. Oncogene, 18, 2892-2900. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Chai, N., Xie, H.H., Yin, J.P., et al. (2018) FOXM1 Promotes Proliferation in Human Hepatocellular Carcinoma Cells by Transcriptional Activation of CCNB1. Biochemical and Biophysical Research Communications, 500, 924-929. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Hoffmann, T.K., Trellakis, S., Okulicz, K., et al. (2011) Cyclin B1 Expression and P53 Status in Squamous Cell Carcinomas of the Head and Neck. Anticancer Research, 31, 3151-3157.
|
|
[26]
|
Zhou, L., Li, J., Zhao, YP., et al. (2014) The Prognostic Value of Cyclin B1 in Pancreatic Cancer. Medical Oncology, 31, Article No. 107. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Wang, X.X., Wu, H.Y., Yang, Y., et al. (2023) CCNB1 Is Involved in Bladder Cancer Pathogenesis and Silencing CCNB1 Decelerates Tumor Growth and Improves Prognosis of Bladder Cancer. Experimental and Therapeutic Medicine, 26, Article No. 382. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Zhu, C., Bossy-Wetzel, E. and Jiang, W. (2005) Recruitment of MKLP1 to the Spindle Midzone/Midbody by INCENP Is Essential for Midbody Formation and Completion of Cytokinesis in Human Cells. Biochemical Journal, 389, 373-381. [Google Scholar] [CrossRef]
|
|
[29]
|
Rath, O. and Kozielski, F. (2012) Kinesins and Cancer. Nature Reviews Cancer, 12, 527-539. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Neef, R., Klein, U.R., Kopajtich, R., et al. (2006) Cooperation Between Mitotic Kinesins Controls the Late Stages of Cytokinesis. Current Biology, 16, 301-307. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Fischer, M., Grundke, I., Sohr, S., et al. (2013) P53 and Cell Cycle Dependent Transcription of Kinesin Family Member 23 (KIF23) Is Controlled via a CHR Promoter Element Bound by DREAM and MMB Complexes. PLOS ONE, 8, e63187. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Iltzsche, F., Simon, K., Stopp, S., et al. (2017) An Important Role for Myb-MuvB and Its Target Gene KIF23 in a Mouse Model of Lung Adenocarcinoma. Oncogene, 36, 110-121. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Zou, J.X., Duan, Z., Wang, J., et al. (2014) Kinesin Family Deregulation Coordinated by Bromodomain Protein ANCCA and Histone Methyltransferase MLL for Breast Cancer Cell Growth, Survival, and Tamoxifen Resistance. Molecular Cancer Research, 12, 539-549. [Google Scholar] [CrossRef]
|
|
[34]
|
Murakami, H., Ito, S., Tanaka, H., et al. (2013) Establishment of New Intraperitoneal Paclitaxel-Resistant Gastric Cancer Cell Lines and Comprehensive Gene Expression Analysis. Anticancer Research, 33, 4299-4307.
|
|
[35]
|
Vikberg, A.L., Vooder, T., Lokk, K., et al. (2017) Mutation Analysis and Copy Number Alterations of KIF23 in Non-Small-Cell Lung Cancer Exhibiting KIF23 Over-Expression. OncoTargets and Therapy, 10, 4969-4979. [Google Scholar] [CrossRef]
|
|
[36]
|
Kato, T., Wada, H., Patel, P., et al. (2016) Overexpression of KIF23 Predicts Clinical Outcome in Primary Lung Cancer Patients. Lung Cancer, 92, 53-61. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Hu, Y., Zheng, M., Wang, C., et al. (2020) Identification of KIF23 as a Prognostic Signature for Ovarian Cancer Based on Large-Scale Sampling and Clinical Validation. American Journal of Translational Research, 12, 4955-4976. [Google Scholar] [CrossRef]
|
|
[38]
|
Bai, X., Cao, Y., Yan, X., et al. (2021) Systematic Pan-Cancer Analysis of KIF23 and a Prediction Model Based on KIF23 in Clear Cell Renal Cell Carcinoma (CcRCC). Pharmacogenomics and Personalized Medicine, 14, 1717-1729. [Google Scholar] [CrossRef]
|